



THE TECHNOLOGY

This technology platform involves methods for drug discovery, disease treatment, and diagnosis using metabolomics. The small molecule profiles of cells subjected to different conditions are compared to identify specific small molecules that are modulated by those conditions. The small molecules detected by this platform comprise many classes of biochemicals including amino acids, carbohydrates, lipids, energy metabolites, co-factors, nucleotides, as well as, xenobiotics.

Patents	US 7,005,255, US 7,329,489, US 7,682,783, US 7,682,784, US 7,635,556, US 7,550,258, US 7,550,260
Issued	Feb 28, 2006, Feb 12, 2008, Mar 23, 2010, Mar 23, 2010, Dec 22, 2009, Jun 23, 2009, Jun 23, 2009
Inventor	Bruce Kristal
Licensee	Metabolon, Inc.

THE PRODUCTS

mVision™

mVision™ is an integrated service platform designed to help industrial clients identify biochemical biomarkers from numerous chemical classes and various biological sample types including plasma, serum, urine, cerebrospinal fluid, cell extracts, and tissues. The mVision™ service provides clients with a biomarker discovery analysis in the context of the metabolic pathways effected enabling them to understand disease processes and to evaluate drug effects *in vitro*, *in vivo*, and in human clinical studies.

mView™

mView™ provides metabolomics-driven biochemical profiling for scientists in academic and government institutions. An mView™ study detects and quantifies the biochemical changes that occur in cells under different conditions by comparing the small molecule profiles of samples under each condition. The study involves quantifying hundreds of biochemicals in each sample, e.g. amino acids, carbohydrates, lipids, cofactors, and nucleosides.